<DOC>
	<DOCNO>NCT02843035</DOCNO>
	<brief_summary>Primary Objective : Part 1 : - Evaluate central nervous system ( CNS ) biomarkers adult Gaucher disease ( GD ) type 3 ( GD3 ) patient distinguish GD3 Gaucher disease type 1 ( GD1 ) . - Screen adult GD3 patient qualify treatment GZ/SAR402671 Part 2 . Part 2 : - Evaluate safety tolerability GZ/SAR402671 adult GD3 patient . - Evaluate change cerebrospinal fluid ( CSF ) central nervous system ( CNS ) biomarkers adult GD3 patient receive GZ/SAR402671 . Secondary Objectives : - Evaluate pharmacokinetics GZ/SAR402671 adult GD3 patient . - Explore efficacy GZ/SAR402671 infiltrative lung disease ( IDL ) adult GD3 patient . - Explore efficacy GZ/SAR402671 systemic disease adult GD3 patient . - Explore efficacy GZ/SAR402671 neurological function exploratory CSF biomarkers adult GD3 patient .</brief_summary>
	<brief_title>GZ/SAR402671 Combination With Cerezyme Adult Patients With Gaucher Disease Type 3</brief_title>
	<detailed_description>The total duration GD1 patient 45 day GD3 patient , total duration 61 week .</detailed_description>
	<mesh_term>Gaucher Disease</mesh_term>
	<criteria>Inclusion criterion : Provide write informed consent prior studyrelated procedure perform . Has clinical diagnosis GD1 GD3 document deficiency acid betaglucosidase activity . Hemoglobin level ≥11.0 g/dL female ≥12.0 g/dL male . Platelet count ≥100 000/mm^3 . Spleen volume &lt; 10 multiple normal ( MN ) . Liver volume &lt; 1.5 MN . No bone crisis free symptomatic bone disease bone pain attributable osteonecrosis and/or pathological fracture within last year . Received treatment ERT least 3 year . For least 6 month prior enrollment , receive Cerezyme stable monthly dose must continue monthly dose study . Female childbearing potential must negative pregnancy test ( urine betahuman chorionic gonadotropin [ βhCG ] ) baseline . If patient history seizure , except myoclonic seizure , well control appropriate medication identify strong moderate inducer inhibitor CYP3A . Adult GD1 cohort : GD1 patient ≥18 ≤40 year age . Adult GD3 cohort : GD3 patient ≥18 year age . Willing abstain consumption grapefruit , grapefruit juice , grapefruit product 72 hour prior administration first dose GZ/SAR402671 duration 52week treatment period . Oculomotor apraxia characterize horizontal saccade abnormality . Cerezyme treatment every 2 week ( minimum dose 30 U/kg every 2 week ) . Females childbearing potential male must willing practice true abstinence line prefer usual lifestyle , use 2 acceptable effective method contraception . Exclusion criterion : Substrate reduction therapy chaperone therapy GD within 6 month prior enrollment . Partial splenectomy within 3 year prior enrollment , total splenectomy . The patient blood transfusiondependent . Prior esophageal varix liver infarction current liver enzyme ( alanine aminotransferase [ ALT ] /aspartate aminotransferase [ AST ] ) total bilirubin &gt; 2 time upper limit normal , unless patient diagnosis Gilbert Syndrome . Clinically significant congenital cardiac defect , coronary artery disease , valve disease leave sided heart failure ; clinically significant arrhythmias conduction defect . Has clinically significant disease , GD , include cardiovascular , renal , hepatic , gastrointestinal , pulmonary , neurologic , endocrine , metabolic ( eg , hypokalemia , hypomagnesemia ) , psychiatric disease , medical condition , serious intercurrent illness may preclude participation . Received investigational product within 30 day prior enrollment . Has history cancer , exception basal cell carcinoma . Has myoclonic seizure . Pregnant lactating . Has WHO grade 2 high cortical posterior subcapsular cataract . Requires use invasive ventilatory support require use noninvasive ventilator support awake longer 12 hour daily . Unable receive treatment Cerezyme due know hypersensitivity unwilling receive Cerezyme treatment every 2 week . Currently receive potentially cataractogenic medication . Has receive strong moderate inducer inhibitor CYP3A within 30 day 5 halflives screen , whichever longer , prior enrolment Part 2 . This also include consumption grapefruit , grapefruit juice , grapefruit containing product within 72 hour start GZ/SAR402671 administration Scheduled inpatient hospitalization include elective surgery , study . Has major organ transplant ( eg , bone marrow liver ) . The patient , opinion Investigator , unable adhere requirement study . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>